University of Crete (UOC)
Φάσης ΙΙ μελέτη υψηλών δόσεων χημειοθεραπείας (μεγαθεραπείας) με ανάνηψη αρχέγονων αιμοποιητικών κυττάρων σε πρώιμο αλλά υψηλού κινδύνου καρκίνο μαστού
Abstract
dc:descriptionTHE PURPOSE OF THIS STUDY WAS TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT HIGH DOSE THERAPY WITH THE TMJ REGIMEN (THIOTEPA 750 MG/M _2,MITOXANTHRONE 40 MG/M2 AND CARBOPLATIN - JM8 1000 MG/M_2) IN PATIENTS WITH STAGE II AND IIIA BREAST CANCER AND 10 OR MORE INVOLVED AXILLARY LYMPH NODES. 74 PATIENTS WERE ENROLLED IN THIS PROSPECTIVE TRIAL. THEY ALL HAD 3-4 CYCLES OF STANDARD DOSE CHEMOTHERAPY WITH A DOXORUBICIN BASED REGIMEN, AFTER ADEQUATE SURGERY. THEY THEN, PROCEEDED TO HIGH DOSE THERAPY WITH ONE CYCLE OF TMJ AND AUTOLOGOUS BONE MARROW AND/OR PERIPHERAL STEM CELL SUPPORT. HIGH DOSE THERAPY WAS FOLLOWED BY RADIATION THERAPY TO THE CHEST WALL, SUPRACLAVICULAR AREA AND INTERNAL MAMMARY GLANDS, AFTER HEMATOPOIETIC RECOVERY. ALL HORMONE RECEPTOR POSITIVE PATIENTS WERE THEN STARTED ON TAMOXIFEN. MEDIAN AGE OF THE PATIENTS WAS 47 (21-64), ECOGPERFORMANCE STATUS 0 IN ALL PATIENTS, 51 PATIENTS WERE PREMENOPAUSAL, 57 HADSTAGE II DISEASE AND 17 STAGE III A. HORMONE RECEPTOR STATUS WAS KNOWN IN ONLY 63 PATIENTS AND OF THOSE, HALF WERE POSITIVE. 67 OF 74 HAD INVASIVE DUCTAL CANCER AND THE VAST MAJORITY UNDERWENT MODIFIED RADICAL MASTECTOMY (88%). THERE WERE NO TREATMENT RELATED DEATHS. MOST PATIENTS (86%) DEVELOPED GRADE 2-4 MUOSITIS AND ALL PATIENTS HAD NEUTROPENIC FEVER. RENAL, HEPATIC, PULMONARY ANDCARDIAC TOXICITY WAS MINIMAL IN COMPARISON TO OTHER HIGH DOSE REGIMENS, AND IN ALL CASES WAS TRANSIENT AND REVERSIBLE. THE MEAN DAYS OF HOSPITAL STAY WERE 24. THE MEDIAN TIME FOR RECOVERY TO WBC 1000 X 10/L WAS 17 DAYS AND FOR A PLATELET COUNT OF 20.000 X 10/L (ABSTARCT TRUNCATED)
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 1998
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ραζή, Ευαγγελία
Subjects
dc:subject × 18- Adjuvant therapy
- Autologous bone marrow
- Breast cancer
- High dose therapy
- High risk disease
- Peripheral stem cells
- Thiotepa, mitoxanthron, carboplatin
- Thiotepa, μιτοξανθρόνη, καρβοπλατίνη
- Αρχέγονα αιμοποιητικά κύτταρα
- Αυτόλογος μυελός
- Επικουρική θεραπεία
- Καρκίνος μαστού
- Μεγαθεραπεία
- Νόσος υψηλού κινδύνου
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/11337